- Home
- NEGG vs CHRS Comparison
NEGG vs CHRS Comparison
Compare NEGG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | CHRS |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.7M | 296.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NEGG | CHRS |
|---|---|---|
| Price | $18.69 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 94.8K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.95 | $0.72 |
| 52 Week High | $137.84 | $2.62 |
Technical Indicators
Market Signals| Indicator | NEGG | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 38.59 |
| Support Level | $16.56 | $1.37 |
| Resistance Level | $21.95 | $1.42 |
| Average True Range (ATR) | 2.19 | 0.08 |
| MACD | 0.66 | -0.01 |
| Stochastic Oscillator | 42.39 | 18.52 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.